10-Q/A: Centessa Pharmaceuticals Files Amended Quarterly Report Due to Omitted Insider Trading Plan Disclosures
Quarterly Report Amendment
Centessa Pharmaceuticals filed an amendment to its Q3 2024 report to include disclosures of Rule 10b5-1 trading plans adopted by certain officers.
Summary
- Centessa Pharmaceuticals filed an amendment (Form 10-Q/A) to its original Q3 2024 report (Form 10-Q) which was filed on November 12, 2024.
- The amendment was filed to revise Part II Item 5, Other Information, to include disclosures of Rule 10b5-1 trading arrangements entered into by Karen Anderson, Tia Bush, Iqbal Hussain, and Harris Rotman during the quarter ended September 30, 2024.
- These disclosures were inadvertently omitted from the original filing.
- The company's CEO and CFO provided certifications for the amended report.
- The amendment does not change the financial statements or any other information in the original filing, except for the added disclosures regarding the Rule 10b5-1 trading plans.
- As of November 1, 2024, the company had 113,845,476 ordinary shares outstanding.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing is simply correcting an omission. There are no indications of positive or negative performance, just a procedural update.
Negatives
- The original filing was incomplete, requiring an amendment.
Risks
- The need to file an amendment suggests potential weaknesses in internal controls over financial reporting.
Future Outlook
The document does not contain any specific forward-looking statements beyond the expiration dates of the Rule 10b5-1 plans.
Industry Context
Rule 10b5-1 plans are common tools used by corporate insiders to sell company stock while avoiding accusations of insider trading. Disclosing these plans is a standard regulatory requirement.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Senior Vice President Regulatory Affairs | Harris Rotman | Departure from the Company |
Stakeholder Impact
- The disclosure of insider trading plans provides transparency to shareholders.
Key Dates
| Date | Description |
|---|---|
| June 20, 2023 | Harris Rotman adopted a Rule 10b5-1 plan. |
| July 17, 2024 | Harris Rotman terminated a Rule 10b5-1 plan. |
| September 13, 2024 | Karen Anderson entered into a Rule 10b5-1 plan. |
| September 14, 2024 | Tia Bush entered into a Rule 10b5-1 plan. |
| September 14, 2024 | Iqbal Hussain entered into a Rule 10b5-1 plan. |
| September 30, 2024 | End of the fiscal quarter for the original 10-Q filing. |
| November 1, 2024 | Date of outstanding ordinary shares count (113,845,476). |
| November 12, 2024 | Original Form 10-Q filing date. |
| December 10, 2024 | Start date for potential sale of shares under Tia Bush's Rule 10b5-1 plan. |
| December 13, 2024 | Start date for potential sale of shares under Karen Anderson's Rule 10b5-1 plan. |
| December 14, 2024 | Start date for potential sale of shares under Iqbal Hussain's Rule 10b5-1 plan. |
| August 15, 2025 | Expiration date for Karen Anderson's Rule 10b5-1 plan. |
| December 15, 2025 | Expiration date for Tia Bush's and Iqbal Hussain's Rule 10b5-1 plans. |
| February 14, 2025 | Date of the amended filing (Form 10-Q/A). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.